FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, [	D.C.	20549
---------------	------	-------

STATEMENT OF	CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	burden									
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Keros Therapeutics, Inc. [ KROS ]							5 (0	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
GORDON CARL L													X	Directo	or		10% Ov	/ner
	ROS THER	APEUTICS, INC		06	3. Date of Earliest Transaction (Month/Day/Year) 06/01/2022									Officer (give title below)			Other (specify below)	
99 HAYDEN AVENUE, SUITE 120, BUILDING E				3 E 4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street)	TON M	A (	02421									ine) X	'				- 1	
(City)	(S	tate) (	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			Transaction ite onth/Day/Ye	Execution Date		Code (Instr.   5)			ed (A) or tr. 3, 4 a	4 and Securiti Benefic		es Formially (D) (Following (I) (I		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code V Amount					(A) or (D)	Price	•	Transaction(s) (Instr. 3 and 4)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year)		Code (	ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Se (In	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expira Date	tion	Title	Amount or Number of Shares	r					
Stock Options (right to buy)	\$32.95	06/01/2022		A		8,293		(1)	05/31/2	2032	Common Stock	8,293		\$0.00	8,293		D <sup>(2)</sup>	

## **Explanation of Responses:**

- 1. The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
- 2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

## Remarks:

/s/ Keith Regnante, Attorney-06/03/2022 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.